Oric Pharmaceuticals
ORIC
101 hedge funds and large institutions have $182M invested in Oric Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 22 increasing their positions, 28 reducing their positions, and 12 closing their positions.
175% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 12
26% more funds holding
Funds holding: 80 → 101 (+21)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
2.24% less ownership
Funds ownership: 88.52% → 86.27% (-2.2%)
21% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 28
65% less capital invested
Capital invested by funds: $512M → $182M (-$330M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
+$17.6M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
+$7.69M |
| 3 |
Alkeon Capital Management
New York
|
+$4.32M |
| 4 |
Millennium Management
New York
|
+$3.4M |
| 5 |
Two Sigma Investments
New York
|
+$2.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$15.8M |
| 2 |
Jennison Associates
New York
|
-$14.5M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$13.4M |
| 4 |
State Street
Boston,
Massachusetts
|
-$6.11M |
| 5 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$5.55M |
ORIC Hedge Fund Activity: Q1 2022 in Review
101 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Oric Pharmaceuticals (ORIC) for Q1 2022, worth a combined $182M — down 65% from $512M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new ORIC positions and 12 closed out — a net gain of 21 holders — while 22 added to existing stakes and 28 trimmed.
The largest buyer was First Manhattan, opening a new position worth an estimated $17.6M. The largest seller was Victory Capital Management, cutting an estimated $15.8M.
- 101 institutional investors held Oric Pharmaceuticals (ORIC) as of Q1 2022, up from 80 in Q4 2021.
- Funds reported $182M of Oric Pharmaceuticals stock for Q1 2022, down 65% quarter-over-quarter.
- 33 funds opened new Oric Pharmaceuticals positions in Q1 2022 and 12 closed out, a net change of +21 holders.
- The largest Oric Pharmaceuticals buyer in Q1 2022 was First Manhattan, an estimated $17.6M added.
- The largest Oric Pharmaceuticals seller in Q1 2022 was Victory Capital Management, an estimated $15.8M sold.
Based on aggregated 13F filings for Q1 2022.